Multiple sclerosis is an acquired chronic immune-mediated inflammatory disease of the brain and the spinal cord characterized by presence of multiple discrete areas of myelin loss within the CNS and subsequent axonal degeneration.
Affects more women than man; however, men are more likely to have a malignant clinical course.
A multiple sclerosis attack is usually characterized by any neurological disturbance with minimum 24 hours duration, in the absence of fever or infection.
Low levels of sun exposure throughout childhood appears to be associated with an increased risk of developing multiple sclerosis in adulthood, a study reports. Notably, the risk is greatest in those who spend most time indoors and use sun protection frequently in their limited time outdoors.
Fingolimod was superior to the standard of care, interferon beta-1a, in reducing relapses and lesion accumulation in children and adolescents with multiple sclerosis (MS) over 2 years, although the treatment was associated with more serious adverse events than the comparator, according to the landmark PARADIGMS study, which forms the basis for the recent expansion of FDA’s approval of this drug to include children and adolescents.
High intake of fish enriched with omega-3 polyunsaturated fatty acids (PUFAs) combined with fish oil supplements were associated with a lower risk of developing multiple sclerosis (MS), according to the MS Sunshine Study presented at the AAN 2018 Annual Meeting.
Cessation of natalizumab treatment just after conception and prompt resumption after delivery may reduce the risk of disease relapse in pregnant women with relapsing-remitting multiple sclerosis (MS), a new study has shown.
A vestibular rehabilitation programme (BEEMS*) integrating balance and eye movement exercises can help improve balance, dizziness, and fatigue in patients with multiple sclerosis (MS), who commonly encountered these problems which can lead to falls and limited mobility, according to a new study.
Treating newly diagnosed relapsing-remitting multiple sclerosis (RRMS) with the anti-CD20 B-cell depleting agent rituximab led to less treatment discontinuation and disease relapse compared with traditional first-line disease-modifying treatment (DMT) choices, according to a Swedish real-world study.
The off-label use of rituximab in the treatment of multiple sclerosis (MS) confers better outcomes than otherdisease-modifying therapies (DMTs), according to a Swedish observational study. [JAMA Neurol 2018, doi: 10.1001/jamaneurol.2017.4011]
High energy intake from fat, particularly saturated fat, appears to increase the hazard to relapse in children with multiple sclerosis (MS), but eating vegetables may be independently protective, suggests a recent study.
Traumatic brain injury, which is signalled by more than one concussion diagnosis, during adolescence presents an increased risk of developing multiple sclerosis, a study suggests. This increased MS risk may be attributed to the initiation of an autoimmune process in the central nervous system.
Ozanimod ─ a novel selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator ─ led to greater reduction in relapse rate and brain atrophy in patients with relapsing multiple sclerosis (MS) in a head-to-head comparison with the first-line treatment interferon β-1a (IFN), according to the SUNBEAM and RADIANCE trials presented at the ECTRIMS-ACTRIMS Meeting 2017 held in Paris, France.